Retinoblastoma is a rare cancer of the infant retina that is diagnosed in approximately 8,000 children each year worldwide. It forms when both retinoblastoma gene (RB1) alleles are mutated in a susceptible retinal cell, probably a cone photoreceptor precursor. Loss of the tumour-suppressive functions of the retinoblastoma protein (pRB) leads to uncontrolled cell division and recurrent genomic changes during tumour progression. Although pRB is expressed in almost all tissues, cone precursors have biochemical and molecular features that may sensitize them to RB1 loss and enable tumorigenesis. Patient survival is >95% in high-income countries but <30% globally. However, outcomes are improving owing to increased disease awareness for earlier diagnosis, application of new guidelines and sharing of expertise. Intra-arterial and intravitreal chemotherapy have emerged as promising methods to salvage eyes that with conventional treatment might have been lost. Ongoing international collaborations will replace the multiple different classifications of eye involvement with standardized definitions to consistently assess the eligibility, efficacy and safety of treatment options. Life-long follow-up is warranted, as survivors of heritable retinoblastoma are at risk for developing second cancers. Defining the molecular consequences of RB1 loss in diverse tissues may open new avenues for treatment and prevention of retinoblastoma, as well as second cancers, in patients with germline RB1 mutations.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
Interruption of aberrant chromatin looping is required for regenerating RB1 function and suppressing tumorigenesis
Communications Biology Open Access 29 September 2022
Cell Death & Disease Open Access 12 September 2022
Cell Death & Disease Open Access 02 June 2022
Subscribe to Journal
Get full journal access for 1 year
only $79.00 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Knudson, A. G. Two genetic hits (more or less) to cancer. Nat. Rev. Cancer 1, 157–162 (2001).
Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
Dimaras, H. et al. Loss of RB1 induces non-proliferative retinoma: increasing genomic instability correlates with progression to retinoblastoma. Hum. Mol. Genet. 17, 1363–1372 (2008). This article provides the first evidence that retinoma is the consequence of two RB1 mutations and not the result of spontaneous tumour regression, and that additional genomic changes are necessary for progression to malignancy.
Dimaras, H. et al. Retinoblastoma. Lancet 379, 1436–1446 (2012).
Seregard, S., Lundell, G., Svedberg, H. & Kivela, T. Incidence of retinoblastoma from 1958 to 1998 in northern Europe: advantages of birth cohort analysis. Ophthalmology 111, 1228–1232 (2004).
Kivela, T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br. J. Ophthalmol. 93, 1129–1131 (2009).
Broaddus, E., Topham, A. & Singh, A. D. Incidence of retinoblastoma in the USA: 1975–2004. Br. J. Ophthalmol. 93, 21–23 (2009).
Nyamori, J. M., Kimani, K., Njuguna, M. W. & Dimaras, H. The incidence and distribution of retinoblastoma in Kenya. Br. J. Ophthalmol. 96, 141–143 (2012).
Canadian Retinoblastoma Society. National Retinoblastoma Strategy Canadian Guidelines for Care. Can. J. Ophthalmol. 44, S1–S88 (2009). The first evidence-based national guidelines for care to be published, showing that consensus at the national level is possible for coordinated care of patients.
MacCarthy, A. et al. Retinoblastoma in Great Britain 1963–2002. Br. J. Ophthalmol. 93, 33–37 (2009). This paper describes the epidemiology of retinoblastoma for a large historical study sample (> 1,600 patients) from Great Britain over four decades.
Krishna, S. M., Yu, G. P. & Finger, P. T. The effect of race on the incidence of retinoblastoma. J. Pediatr. Ophthalmol. Strabismus 46, 288–293 (2009).
Moreno, F. et al. A population-based study of retinoblastoma incidence and survival in Argentine children. Pediatr. Blood Cancer 61, 1610–1615 (2014).
One Retinoblastoma World. One Retinoblastoma World map. 1rbw[online], (2015). A ‘virtual’ retinoblastoma clinic that documents resources and expertise available for retinoblastoma treatment around the world, juxtaposed against expected new annual retinoblastoma cases per country. This sets the stage for a learning health system for retinoblastoma.
Nyawira, G., Kahaki, K. & Kariuki-Wanyoike, M. Survival among retinoblastoma patients at the Kenyatta National Hospital, Kenya. J. Ophthalmol. Eastern Central Southern Africa 17, 15–19 (2013).
Dean, M. et al. Increased incidence and disparity of diagnosis of retinoblastoma patients in Guatemala. Cancer Lett. 351, 59–63 (2014).
Kumar, A., Moulik, N. R., Mishra, R. K. & Kumar, D. Causes, outcome and prevention of abandonment in retinoblastoma in India. Pediatr. Blood Cancer 60, 771–775 (2013).
Gichigo, E. N., Kariuki-Wanyoike, M. M., Kimani, K. & Nentwich, M. M. Retinoblastoma in Kenya: survival and prognostic factors. Ophthalmologe 112, 255–260 (in German) (2014).
Asencio-Lopez, L., Torres-Ojeda, A. A., Isaac-Otero, G., Rosales Lopez, S. L. & Leal-Leal, C. A. Treating retinoblastoma in the first year of life in a national tertiary pediatric hospital in Mexico. Acta Paediatr. http://dx.doi.org/10.1111/apa.13033 (2015).
Kenyan Ministry of Health. Kenya National Retinoblastoma Strategy: Best Practice Guidelines. Kenyan Ministry of Health[online], (2014).
Vincent, A. L., Webb, M. C., Gallie, B. L. & Heon, E. Prosthetic conformers: a step towards improved rehabilitation of enucleated children. Clin. Experiment. Ophthalmol. 30, 58–59 (2002). This paper shows that implantation of an artificial eye during the enucleation surgery instead of months later improves psychosocial acceptance and coping.
Dimaras, H., White, A. & Gallie, B. L. The Kenyan National Retinoblastoma Strategy: building local capacity in the diagnosis and management of pediatric eye cancer in Kenya. Ophthalmology Rounds [online], (2008).
Chantada, G. et al. SIOP-PODC recommendations for graduated-intensity treatment of retinoblastoma in developing countries. Pediatr. Blood Cancer 60, 719–727 (2013).
Perez-Cuevas, R. et al. Scaling up cancer care for children without medical insurance in developing countries: the case of Mexico. Pediatr. Blood Cancer 60, 196–203 (2013).
de Castro Junior, C. G. & Macedo, C. R. Brazilian Society of Pediatric Oncology — SOBOPE: 30 years of history, a lot in the present, full of the future. Rev. Bras. Hematol. Hemoter. 33, 326–327 (2011).
Naseripour, M. “Retinoblastoma survival disparity”: the expanding horizon in developing countries. Saudi J. Ophthalmol. 26, 157–161 (2012).
Qaddoumi, I. et al. Team management, twinning, and telemedicine in retinoblastoma: a 3-tier approach implemented in the first eye salvage program in Jordan. Pediatr. Blood Cancer 51, 241–244 (2008).
Wilimas, J. A. et al. Development of retinoblastoma programs in Central America. Pediatr. Blood Cancer 53, 42–46 (2009).
Traore, F. et al. [Retinoblastoma: inventory in Mali and program to develop early diagnosis, treatments and rehabilitation]. Bull. Cancer 100, 161–165 (in French) (2013).
Luna-Fineman, S. et al. Retinoblastoma in Central America: report from the Central American Association of Pediatric Hematology Oncology (AHOPCA). Pediatr. Blood Cancer 58, 545–550 (2012). This article shows that multicentre studies in lower middle-income countries are feasible.
Barr, R. D. et al. Asociacion de Hemato-Oncologia Pediatrica de Centro America (AHOPCA): a model for sustainable development in pediatric oncology. Pediatr. Blood Cancer 61, 345–354 (2014).
Waddell, K. M. et al. Improving survival of retinoblastoma in Uganda. Br. J. Ophthalmol. 99, 937–942 (2015).
Waddell, K. M. et al. Clinical features and survival among children with retinoblastoma in Uganda. Br. J. Ophthalmol. 99, 387–390 (2015).
Schvartzman, E. et al. Results of a stage-based protocol for the treatment of retinoblastoma. J. Clin. Oncol. 14, 1532–1536 (1996).
Chantada, G. L. et al. Results of a prospective study for the treatment of unilateral retinoblastoma. Pediatr. Blood Cancer 55, 60–66 (2010). This prospective study of a national referral centre in Argentina shows improved results with tailored chemotherapy regimens according to pathological risk factors.
Chantada, G. L. et al. Impact of chemoreduction for conservative therapy for retinoblastoma in Argentina. Pediatr. Blood Cancer 61, 821–826 (2014).
Chiu, H. H., Dimaras, H., Downie, R. & Gallie, B. Breaking down barriers to communicating complex retinoblastoma information: can graphics be the solution? Can. J. Ophthalmol. 50, 230–235 (2015).
Knudson, A. G. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl Acad. Sci. USA 68, 820–823 (1971). This paper provides the first model of retinoblastoma development and suggests that two hits are necessary for tumour initiation. This set the stage for the discovery that cancer is a genetic disease, requiring inactivation of each allele of a gene.
Comings, D. E. A general theory of carcinogenesis. Proc. Natl Acad. Sci. USA 70, 3324–3328 (1973).
Cavenee, W. K. et al. Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 305, 779–784 (1983).
Dryja, T. P., Rapaport, J. M., Joyce, J. M. & Petersen, R. A. Molecular detection of deletions involving band q14 of chromosome 13 in retinoblastomas. Proc. Natl Acad. Sci. USA 83, 7391–7394 (1986).
Friend, S. H. et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 323, 643–646 (1986). Following on from the research detailed in reference 40, this paper reports the isolation of a 70 kb cDNA fragment of the gene that predisposes individuals to retinoblastoma and osteosarcoma, setting the stage for the identification of RB1.
Lee, W. H. et al. Human retinoblastoma susceptibility gene: cloning, identification, and sequence. Science 235, 1394–1399 (1987).
Fung, Y. K. et al. Structural evidence for the authenticity of the human retinoblastoma gene. Science 236, 1657–1661 (1987).
Lohmann, D. R. RB1 gene mutations in retinoblastoma. Hum. Mutat. 14, 283–288 (1999).
McEvoy, J. et al. RB1 gene inactivation by chromothripsis in human retinoblastoma. Oncotarget 5, 438–450 (2014).
Dick, F. A. & Rubin, S. M. Molecular mechanisms underlying RB protein function. Nat. Rev. Mol. Cell Biol. 14, 297–306 (2013).
Lohmann, D. R., Brandt, B., Hopping, W., Passarge, E. & Horsthemke, B. Distinct RB1 gene mutations with low penetrance in hereditary retinoblastoma. Hum. Genet. 94, 349–354 (1994).
Lee, T. C., Almeida, D., Claros, N., Abramson, D. H. & Cobrinik, D. Cell cycle-specific and cell type-specific expression of Rb in the developing human retina. Invest. Ophthalmol. Vis. Sci. 47, 5590–5598 (2006).
Goodrich, D. W. How the other half lives, the amino-terminal domain of the retinoblastoma tumor suppressor protein. J. Cell. Physiol. 197, 169–180 (2003).
Cook, R. et al. Direct involvement of retinoblastoma family proteins in DNA repair by non-homologous end-joining. Cell Rep. 10, 2006–2018 (2015).
Theriault, B. L., Dimaras, H., Gallie, B. L. & Corson, T. W. The genomic landscape of retinoblastoma: a review. Clin. Experiment. Ophthalmol. 42, 33–52 (2014).
Zhang, J. et al. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 481, 329–334 (2012). This genome-wide study identifies epigenetic SYK dysregulation in retinoblastoma and BCOR mutations in some tumours, and validates SYK inhibition as a therapy in an orthotopic xenograft model.
Kooi, I. E. et al. Loss of photoreceptorness and gain of genomic alterations in retinoblastoma reveal tumor progression. eBio Med. 2, 660–670 (2015).
McEvoy, J. et al. Coexpression of normally incompatible developmental pathways in retinoblastoma genesis. Cancer Cell 20, 260–275 (2011).
Kapatai, G. et al. Gene expression profiling identifies different sub-types of retinoblastoma. Br. J. Cancer 109, 512–525 (2013).
Rushlow, D. E. et al. Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies. Lancet Oncol. 14, 327–334 (2013). By analysing mutation data of >1,000 retinoblastomas, this work identifies a histologically and clinically distinct subset of retinoblastomas with no RB1 mutations but with MYCN amplification, suggesting that retinoblastoma can be initiated either by loss of tumour-suppressor gene function or by oncogene overexpression.
Kyritsis, A. P., Tsokos, M., Triche, T. J. & Chader, G. J. Retinoblastoma — origin from a primitive neuroectodermal cell? Nature 307, 471–473 (1984).
Sangwan, M. et al. Established and new mouse models reveal E2f1 and Cdk2 dependency of retinoblastoma, and expose effective strategies to block tumor initiation. Oncogene 31, 5019–5028 (2012).
Cobrinik, D. in Animal Models of Brain Tumors (eds Martinez-Murillo, R. & Martinez, A. ) 141–152 (Springer, 2013).
Munier, F. L., Balmer, A., van Melle, G. & Gailloud, C. Radial asymmetry in the topography of retinoblastoma. Clues to the cell of origin. Ophthalmic Genet. 15, 101–106 (1994).
Xu, X. L. et al. Retinoblastoma has properties of a cone precursor tumor and depends upon cone-specific MDM2 signaling. Cell 137, 1018–1031 (2009).
Xu, X. L. et al. Rb suppresses human cone-precursor-derived retinoblastoma tumours. Nature 514, 385–388 (2014). This study provides strong evidence of the retinoblastoma cell of origin by showing that knockdown of RB1 induces proliferation of cone precursors in a manner that is dependent on proteins expressed in maturing cones, including MYCN, MDM2 and SKP2.
Rootman, D. B. et al. Hand-held high-resolution spectral domain optical coherence tomography in retinoblastoma: clinical and morphologic considerations. Br. J. Ophthalmol. 97, 59–65 (2013).
Xu, X. L. et al. Tumor-associated retinal astrocytes promote retinoblastoma cell proliferation through production of IGFBP-5. Am. J. Pathol. 177, 424–435 (2010).
Hook, K. E. et al. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735. Mol. Cancer Ther. 11, 710–719 (2012).
Puissant, A. et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 3, 308–323 (2013).
Gallie, B. L., Trogadis, J. & Han, L.-P. in Human Cell Culture. Cancer Cell Lines Part 2 (ed. Masters, J. ) 361–374 (Springer, 1999).
Gallie, B. L., Albert, D. M., Wong, J. J., Buyukmihci, N. & Puliafito, C. A. Heterotransplantation of retinoblastoma into the athymic “nude” mouse. Invest. Ophthalmol. Vis. Sci. 16, 256–259 (1977).
Pacal, M. & Bremner, R. Insights from animal models on the origins and progression of retinoblastoma. Curr. Mol. Med. 6, 759–781 (2006).
Conkrite, K. et al. miR-17∼92 cooperates with RB pathway mutations to promote retinoblastoma. Genes Dev. 25, 1734–1745 (2011).
Windle, J. J. et al. Retinoblastoma in transgenic mice. Nature 343, 665–669 (1990).
Pajovic, S. et al. The TAg-RB murine retinoblastoma cell of origin has immunohistochemical features of differentiated Muller glia with progenitor properties. Invest. Ophthalmol. Vis. Sci. 52, 7618–7624 (2011).
Karcioglu, Z. A. Fine needle aspiration biopsy (FNAB) for retinoblastoma. Retina 22, 707–710 (2002).
de Jong, M. C. et al. Diagnostic performance of magnetic resonance imaging and computed tomography for advanced retinoblastoma: a systematic review and meta-analysis. Ophthalmology 121, 1109–1118 (2014).
de Jong, M. C. et al. Trilateral retinoblastoma: a systematic review and meta-analysis. Lancet Oncol. 15, 1157–1167 (2014).
McCarthy, M. et al. Comfort First: an evaluation of a procedural pain management programme for children with cancer. Psychooncology 22, 775–782 (2013).
Moulin, A. P., Gaillard, M. C., Balmer, A. & Munier, F. L. Ultrasound biomicroscopy evaluation of anterior extension in retinoblastoma: a clinicopathological study. Br. J. Ophthalmol. 96, 337–340 (2012).
Reese, A. B. & Ellsworth, R. M. The evaluation and current concept of retinoblastoma therapy. Trans. Am. Acad. Ophthalmol. Otolaryngol. 67, 164–172 (1963).
Murphree, A. L. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol. Clin. North Am. 18, 41–53 (2005). This article describes the creation of a new classification for retinoblastoma, representing the shift from EBRT to chemotherapy as primary therapy.
Shields, C. L. et al. The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology 113, 2276–2280 (2006).
Novetsky, D. E., Abramson, D. H., Kim, J. W. & Dunkel, I. J. Published International Classification of Retinoblastoma (ICRB) definitions contain inconsistencies — an analysis of impact. Ophthalmic Genet. 30, 40–44 (2009).
Children's OncologyGroup. Newly diagnosed with retinoblastoma. Children's Oncology Group[online], (2011).
Finger, P. T. et al. in AJCC Cancer Staging Manual (eds Edge, S. B., Byrd, D. R., Carducci, M. A. & Compton, C. C. ) 561–568 (Springer, 2010).
Chantada, G. et al. A proposal for an international retinoblastoma staging system. Pediatr. Blood Cancer 47, 801–805 (2006). This paper presents a retinoblastoma staging system that encompasses the full range of the disease, as well as the collaborative work and consensus of multiple specialists from different settings.
Sastre, X. et al. Proceedings of the consensus meetings from the International Retinoblastoma Staging Working Group on the pathology guidelines for the examination of enucleated eyes and evaluation of prognostic risk factors in retinoblastoma. Arch. Pathol. Lab. Med. 133, 1199–1202 (2009). This paper details the development of clear consensus guidelines for the handling of enucleated eyes and the assessment of pathological risk factors.
Wilson, M. W., Qaddoumi, I., Billups, C., Haik, B. G. & Rodriguez-Galindo, C. A clinicopathological correlation of 67 eyes primarily enucleated for advanced intraocular retinoblastoma. Br. J. Ophthalmol. 95, 553–558 (2011).
Sullivan, E. M. et al. Pathologic risk-based adjuvant chemotherapy for unilateral retinoblastoma following enucleation. J. Pediatr. Hematol. Oncol. 36, e335–e340 (2014). This prospective study of non-metastatic unilateral retinoblastomas treated on a graduated intensity chemotherapy protocol shows that all patients were alive at median follow-up of 3.4 years.
Mendoza, P. R. et al. Histopathologic grading of anaplasia in retinoblastoma. Am. J. Ophthalmol. 159, 764–776 (2015).
Yousef, Y. A. et al. Predictive value of TNM classification, international classification, and Reese–Ellsworth staging of retinoblastoma for the likelihood of high-risk pathologic features. Retina http://dx.doi.org/10.1097/IAE.0000000000000547 (2015).
Kaliki, S., Srinivasan, V., Gupta, A., Mishra, D. K. & Naik, M. N. Clinical features predictive of high-risk retinoblastoma in 403 Asian Indian patients: a case–control study. Ophthalmology 122, 1165–1172 (2015). This research paper shows that prolonged duration of symptoms (>6 months) and secondary glaucoma following attempted eye salvage are predictive of high-risk retinoblastoma.
Kim, J. W. Retinoblastoma: evidence for postenucleation adjuvant chemotherapy. Int. Ophthalmol. Clin. 55, 77–96 (2015).
Grossniklaus, H. E., Kivëla, T., Harbour, J. W. & Finger, P. T. Protocol for the examination of specimens from patients with retinoblastoma. CAP [online], (2011).
Torbidoni, A. V. et al. Association of cone–rod homeobox transcription factor messenger RNA with pediatric metastatic retinoblastoma. JAMA Ophthalmol. 133, 805–812 (2015).
Torbidoni, A. V. et al. Immunoreactivity of the 14F7 Mab raised against N-glycolyl GM3 ganglioside in retinoblastoma tumours. Acta Ophthalmol. 93, e294–e300 (2014).
Genetics, I. What is retinoblastoma? Impact Genetics [online], (2015).
Wong, J. R. et al. Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy. J. Clin. Oncol. 32, 3284–3290 (2014).
Xu, K. et al. Preimplantation genetic diagnosis for retinoblastoma: the first reported liveborn. Am. J. Ophthalmol. 137, 18–23 (2004).
Dommering, C. J., Moll, A. C., Imhof, S. M., de Die-Smulders, C. E. & Coonen, E. Another liveborn after preimplantation genetic diagnosis for retinoblastoma. Am. J. Ophthalmol. 138, 1088–1089 (2004).
Dimaras, H. et al. Retinoblastoma CSF metastasis cured by multimodality chemotherapy without radiation. Ophthalmic Genet. 30, 121–126 (2009).
Bowles, E. et al. Profiling genomic copy number changes in retinoblastoma beyond loss of RB1. Genes Chromosomes Cancer 46, 118–129 (2007).
Chantada, G. L. et al. Familial retinoblastoma in developing countries. Pediatr. Blood Cancer 53, 338–342 (2009).
He, L. Q. et al. Developing clinical cancer genetics services in resource-limited countries: the case of retinoblastoma in Kenya. Public Health Genomics 17, 221–227 (2014).
Patel, T. et al. Consumer digital cameras: a feasible strategy for the early detection of childhood blindness. Invest. Ophthalmol. Vis. Sci. 53, 6775 (2012).
Abdolvahabi, A. et al. Colorimetric and longitudinal analysis of leukocoria in recreational photographs of children with retinoblastoma. PLoS ONE 8, e76677 (2013). This study used common software to retrospectively quantify leukocoria in photographs of infants who were diagnosed with retinoblastoma. They identified that the saturation-value plane of the hue, saturation and value colour space are useful for counting and categorizing pupillary reflections.
MacCarthy, A. et al. Second and subsequent tumours among 1927 retinoblastoma patients diagnosed in Britain 1951–2004. Br. J. Cancer 108, 2455–2463 (2013). This retrospective study of a large British patient cohort showed substantial evidence of increased risk of second cancers in patients with heritable retinoblastoma.
Abramson, D. H., Beaverson, K. L., Chang, S. T., Dunkel, I. J. & McCormick, B. Outcome following initial external beam radiotherapy in patients with Reese–Ellsworth group Vb retinoblastoma. Arch. Ophthalmol. 122, 1316–1323 (2004).
Fletcher, O. et al. Lifetime risks of common cancers among retinoblastoma survivors. J. Natl Cancer Inst. 96, 357–363 (2004).
Friedman, D. N. et al. Whole-body magnetic resonance imaging (WB-MRI) as surveillance for subsequent malignancies in survivors of hereditary retinoblastoma: a pilot study. Pediatr. Blood Cancer 61, 1440–1444 (2014).
Soliman, S. E., Dimaras, H., Souka, A. A., Ashry, M. H. & Gallie, B. L. Socioeconomic and psychological impact of treatment for unilateral intraocular retinoblastoma. J. Fr. Ophtalmol. 38, 550–558 (2015). This study shows that globe-salvage therapy produces more negative consequences (for example, family conflict, financial burden and longer treatment duration) than upfront enucleation in low- and middle-income countries.
Shields, C. L. et al. Retinoblastoma frontiers with intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Eye (Lond.) 27, 253–264 (2013).
Eng, C. et al. Mortality from second tumors among long-term survivors of retinoblastoma. J. Natl Cancer Inst. 85, 1121–1128 (1993).
Chantada, G. L. et al. Treatment results in patients with retinoblastoma and invasion to the cut end of the optic nerve. Pediatr. Blood Cancer 52, 218–222 (2009). This paper retrospectively evaluates three treatment modalities for patients for whom histopathological analysis shows tumour invasion to the cut end of the nerve. Results show that cure is possible (event-free survival was 0.70 at 5 years), but not without several treatment-related sequelae.
Kashyap, S. et al. Clinical predictors of high risk histopathology in retinoblastoma. Pediatr. Blood Cancer 58, 356–361 (2012).
Zhao, J. et al. Pre-enucleation chemotherapy for eyes severely affected by retinoblastoma masks risk of tumor extension and increases death from metastasis. J. Clin. Oncol. 29, 845–851 (2011). This paper provides the first evidence that delay in enucleation of >3 months while neoadjuvant chemotherapy is given for an eye with high-risk clinical features (IIRC Group E) results in a significant (P < 0.001) increase in the risk of metastasis and death.
Francis, J. H. et al. Efficacy and toxicity of second-course ophthalmic artery chemosurgery for retinoblastoma. Ophthalmology 122, 1016–1022 (2015).
Hamama-Raz, Y., Rot, I. & Buchbinder, E. The coping experience of parents of a child with retinoblastoma-malignant eye cancer. J. Psychosoc. Oncol. 30, 21–40 (2012).
Mathew, A. A., Sachdev, N., Staffieri, S. E., McKenzie, J. D. & Elder, J. E. Superselective intra-arterial chemotherapy for advanced retinoblastoma complicated by metastatic disease. J. AAPOS 19, 72–74 (2015).
Gunduz, K. et al. Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation. Ophthalmology 111, 1917–1924 (2004).
Manjandavida, F. P., Honavar, S. G., Reddy, V. A. & Khanna, R. Management and outcome of retinoblastoma with vitreous seeds. Ophthalmology 121, 517–524 (2014).
Schaiquevich, P. et al. Intra-arterial chemotherapy is more effective than sequential periocular and intravenous chemotherapy as salvage treatment for relapsed retinoblastoma. Pediatr. Blood Cancer 60, 766–770 (2013). This study compares the efficacy and toxicity of IAC to that of periocular and systemic chemotherapy treatment of a retrospective cohort of patients.
Shields, C. L. et al. Iodine 125 plaque radiotherapy as salvage treatment for retinoblastoma recurrence after chemoreduction in 84 tumors. Ophthalmology 113, 2087–2092 (2006).
Chan, M. P., Hungerford, J. L., Kingston, J. E. & Plowman, P. N. Salvage external beam radiotherapy after failed primary chemotherapy for bilateral retinoblastoma: rate of eye and vision preservation. Br. J. Ophthalmol. 93, 891–894 (2009).
Pica, A. et al. Preliminary experience in treatment of papillary and macular retinoblastoma: evaluation of local control and local complications after treatment with linear accelerator-based stereotactic radiotherapy with micromultileaf collimator as second-line or salvage treatment after chemotherapy. Int. J. Radiat. Oncol. Biol. Phys. 81, 1380–1386 (2011).
Berry, J. L. et al. Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage. Pediatr. Blood Cancer 60, 688–693 (2013). This retrospective review of Group D eyes of patients with bilateral retinoblastoma shows that treatment with primary chemotherapy and focal therapy cured 47% of eyes without EBRT and 68% with rescue by EBRT at 60 months follow-up.
Munier, F. L. et al. New developments in external beam radiotherapy for retinoblastoma: from lens to normal tissue-sparing techniques. Clin. Experiment. Ophthalmol. 36, 78–89 (2008).
Mouw, K. W. et al. Proton radiation therapy for the treatment of retinoblastoma. Int. J. Radiat. Oncol. Biol. Phys. 90, 863–869 (2014).
Shields, C. L. et al. Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation. Am. J. Ophthalmol. 133, 657–664 (2002).
Abramson, D. H. & Schefler, A. C. Update on retinoblastoma. Retina 24, 828–848 (2004).
Gobin, Y. P., Dunkel, I. J., Marr, B. P., Brodie, S. E. & Abramson, D. H. Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch. Ophthalmol. 129, 732–737 (2011). This paper represents a single-arm, prospective study of the safety and efficacy of IAC for patients with advanced unilateral and bilateral intraocular retinoblastoma.
Suzuki, S., Yamane, T., Mohri, M. & Kaneko, A. Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis. Ophthalmology 118, 2081–2087 (2011). This paper is a non-comparative case series reporting on the safety and efficacy on the first ever cohort of patients with retinoblastoma who were treated with IAC.
Shields, C. L. et al. Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma. Ophthalmology 121, 1453–1460 (2014). A retrospective interventional case series of the efficacy of IAC as primary or secondary treatment for retinoblastoma.
Abramson, D. H. et al. Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding: 2-year results. Br. J. Ophthalmol. 96, 499–502 (2012).
Schaiquevich, P. et al. Pharmacokinetic analysis of topotecan after superselective ophthalmic artery infusion and periocular administration in a porcine model. Retina 32, 387–395 (2012).
Munier, F. L. et al. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Br. J. Ophthalmol. 96, 1078–1083 (2012). This paper describes the first use of intravitreal chemotherapy for the treatment of vitreous seeds, which are the most difficult to manage feature of retinoblastoma.
Shields, C. L. et al. Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results. JAMA Ophthalmol. 132, 319–325 (2014).
Francis, J. H. et al. The classification of vitreous seeds in retinoblastoma and response to intravitreal melphalan. Ophthalmology 122, 1173–1179 (2015).
Munier, F. L. Classification and management of seeds in retinoblastoma. Ellsworth Lecture Ghent August 24th 2013. Ophthalmic Genet. 35, 193–207 (2014).
Mallipatna, A. C., Sutherland, J. E., Gallie, B. L., Chan, H. & Heon, E. Management and outcome of unilateral retinoblastoma. J. AAPOS 13, 546–550 (2009).
Mourits, D. L., Hartong, D. T., Bosscha, M. I., Kloos, R. J. & Moll, A. C. Worldwide enucleation techniques and materials for treatment of retinoblastoma: an international survey. PLoS ONE 10, e0121292 (2015).
Yadava, U., Sachdeva, P. & Arora, V. Myoconjunctival enucleation for enhanced implant motility. Result of a randomised prospective study. Indian J. Ophthalmol. 52, 221–226 (2004).
Shome, D., Honavar, S. G., Raizada, K. & Raizada, D. Implant and prosthesis movement after enucleation: a randomized controlled trial. Ophthalmology 117, 1638–1644 (2010). A randomized controlled trial that evaluated eye movement outcome after enucleation by comparing the use of PMMA implants using muscle imbrication or a myoconjunctival technique to the use of porous polyethylene implants after enucleation with the scleral cap technique.
Ferris, F. L. 3rd Chew, E. Y. A new era for the treatment of retinoblastoma. Arch. Ophthalmol. 114, 1412 (1996).
Chan, H. S. et al. Combining cyclosporin with chemotherapy controls intraocular retinoblastoma without requiring radiation. Clin. Cancer Res. 2, 1499–1508 (1996).
Gallie, B. L. et al. Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch. Ophthalmol. 114, 1321–1328 (1996).
Chan, H. S. L. Combination chemotherapy and cyclosporine followed by focal therapy for bilateral retinoblastoma. ClinicalTrials.gov[online], (2005).
Dunkel, I. J. et al. A phase II trial of carboplatin for intraocular retinoblastoma. Pediatr. Blood Cancer 49, 643–648 (2007).
Jehanne, M. et al. Analysis of ototoxicity in young children receiving carboplatin in the context of conservative management of unilateral or bilateral retinoblastoma. Pediatr. Blood Cancer 52, 637–643 (2009).
Draper, G. J., Sanders, B. M. & Kingston, J. E. Second primary neoplasms in patients with retinoblastoma. Br. J. Cancer 53, 661–671 (1986).
Smith, M. A. et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J. Clin. Oncol. 17, 569–577 (1999).
Gombos, D. S. et al. Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor? Ophthalmology 114, 1378–1383 (2007).
Gombos, D. S., Kelly, A., Coen, P. G., Kingston, J. E. & Hungerford, J. L. Retinoblastoma treated with primary chemotherapy alone: the significance of tumour size, location, and age. Br. J. Ophthalmol. 86, 80–83 (2002).
Lee, V. et al. Globe conserving treatment of the only eye in bilateral retinoblastoma. Br. J. Ophthalmol. 87, 1374–1380 (2003).
Shields, C. L. et al. Macular retinoblastoma managed with chemoreduction: analysis of tumor control with or without adjuvant thermotherapy in 68 tumors. Arch. Ophthalmol. 123, 765–773 (2005).
Astudillo, P. P., Chan, H. S., Heon, E. & Gallie, B. L. Late-diagnosis retinoblastoma with germline mosaicism in an 8-year-old. J. AAPOS 18, 500–502 (2014).
Narang, S., Mashayekhi, A., Rudich, D. & Shields, C. L. Predictors of long-term visual outcome after chemoreduction for management of intraocular retinoblastoma. Clin. Experiment. Ophthalmol. 40, 736–742 (2012).
Watts, P. et al. Visual results in children treated for macular retinoblastoma. Eye (Lond.) 16, 75–80 (2002).
Abramson, D. H., Dunkel, I. J., Brodie, S. E., Kim, J. W. & Gobin, Y. P. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology 115, 1398–1404.e1 (2008).
Klufas, M. A. et al. Intra-arterial chemotherapy as a treatment for intraocular retinoblastoma: alternatives to direct ophthalmic artery catheterization. AJNR Am. J. Neuroradiol 33, 1608–1614 (2012).
Abramson, D. H. et al. Ophthalmic artery chemosurgery for less advanced intraocular retinoblastoma: five year review. PLoS ONE 7, e34120 (2012).
Ong, S. J., Chao, A. N., Wong, H. F., Liou, K. L. & Kao, L. Y. Selective ophthalmic arterial injection of melphalan for intraocular retinoblastoma: a 4-year review. Jpn J. Ophthalmol. 59, 109–117 (2015).
Francis, J. H. et al. Electroretinogram monitoring of dose-dependent toxicity after ophthalmic artery chemosurgery in retinoblastoma eyes: six year review. PLoS ONE 9, e84247 (2014).
Abramson, D. H., Frank, C. M. & Dunkel, I. J. A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmology 106, 1947–1950 (1999).
Mallipatna, A. C., Dimaras, H., Chan, H. S., Heon, E. & Gallie, B. L. Periocular topotecan for intraocular retinoblastoma. Arch. Ophthalmol. 129, 738–745 (2011).
Mulvihill, A. et al. Ocular motility changes after subtenon carboplatin chemotherapy for retinoblastoma. Arch. Ophthalmol. 121, 1120–1124 (2003).
Ghassemi, F. & Amoli, F. A. Pathological findings in enucleated eyes after intravitreal melphalan injection. Int. Ophthalmol. 34, 533–540 (2014).
Ghassemi, F., Shields, C. L., Ghadimi, H., Khodabandeh, A. & Roohipoor, R. Combined intravitreal melphalan and topotecan for refractory or recurrent vitreous seeding from retinoblastoma. JAMA Ophthalmol. 132, 936–941 (2014).
Friedman, D. N. et al. Long-term medical outcomes in survivors of extra-ocular retinoblastoma: the Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Pediatr. Blood Cancer 60, 694–699 (2013).
Bansal, M., Patel, F. D., Mohanti, B. K. & Sharma, S. C. Setting up a palliative care clinic within a radiotherapy department: a model for developing countries. Support. Care Cancer 11, 343–347 (2003).
Willard, V. W. et al. Developmental and adaptive functioning in children with retinoblastoma: a longitudinal investigation. J. Clin. Oncol. 32, 2788–2793 (2014).
Brinkman, T. M. et al. Cognitive function and social attainment in adult survivors of retinoblastoma: a report from the St. Jude Lifetime Cohort Study. Cancer 121, 123–131 (2015).
Tobin, M., Hill, E. & Hill, J. Retinoblastoma and superior verbal IQ scores? Br. J. Vis. Impair. 28, 7–18 (2010).
Kelly, K. R., McKetton, L., Schneider, K. A., Gallie, B. L. & Steeves, J. K. Altered anterior visual system development following early monocular enucleation. Neuroimage Clin. 4, 72–81 (2014).
Kelly, K. R., DeSimone, K. D., Gallie, B. L. & Steeves, J. K. Increased cortical surface area and gyrification following long-term survival from early monocular enucleation. Neuroimage Clin. 7, 297–305 (2015).
Gonzalez, E. G., Lillakas, L., Lam, A., Gallie, B. L. & Steinbach, M. J. Horizontal saccade dynamics after childhood monocular enucleation. Invest. Ophthalmol. Vis. Sci. 54, 6463–6471 (2013).
Rappaport, B. A., Suresh, S., Hertz, S., Evers, A. S. & Orser, B. A. Anesthetic neurotoxicity — clinical implications of animal models. N. Engl. J. Med. 372, 796–797 (2015).
Rappaport, B., Mellon, R. D., Simone, A. & Woodcock, J. Defining safe use of anesthesia in children. N. Engl. J. Med. 364, 1387–1390 (2011).
Ing, C. et al. Long-term differences in language and cognitive function after childhood exposure to anesthesia. Pediatrics 130, e476–e485 (2012).
Khin Hla, T. et al. Perception of pediatric pain: a comparison of postoperative pain assessments between child, parent, nurse, and independent observer. Paediatr. Anaesth. 24, 1127–1131 (2014).
Chen, E., Zeltzer, L. K., Craske, M. G. & Katz, E. R. Children's memories for painful cancer treatment procedures: implications for distress. Child Dev. 71, 933–947 (2000).
Dahlquist, L. M. & Pendley, J. S. When distraction fails: parental anxiety and children's responses to distraction during cancer procedures. J. Pediatr. Psychol. 30, 623–628 (2005).
van Dijk, J. et al. Behavioural functioning of retinoblastoma survivors. Psychooncology 18, 87–95 (2009).
van Dijk, J. et al. Coping strategies of retinoblastoma survivors in relation to behavioural problems. Psychooncology 18, 1281–1289 (2009).
Gold, J. I. PTSD can affect sick kids? Your medical PTSD questions answered. RESEARCHLA Blog (Children's Hospital Los Angeles, The Saban Research Institute, Los Angeles) [online], (2015).
Committee on Hospital Care and Child Life Council. Child Life services. Pediatrics 133, e1471–e1478 (2014).
O’Callaghan, C., Sexton, M. & Wheeler, G. Music therapy as a non-pharmacological anxiolytic for paediatric radiotherapy patients. Australas. Radiol. 51, 159–162 (2007).
Post-White, J. et al. Massage therapy for children with cancer. J. Pediatr. Oncol. Nurs. 26, 16–28 (2009).
Hildenbrand, A. K., Clawson, K. J., Alderfer, M. A. & Marsac, M. L. Coping with pediatric cancer: strategies employed by children and their parents to manage cancer-related stressors during treatment. J. Pediatr. Oncol. Nurs. 28, 344–354 (2011).
van Dijk, J. et al. Restrictions in daily life after retinoblastoma from the perspective of the survivors. Pediatr. Blood Cancer 54, 110–115 (2010).
van Dijk, J. et al. Quality of life of adult retinoblastoma survivors in the Netherlands. Health Qual. Life Outcomes 5, 30 (2007).
Shinohara, E. T., DeWees, T. & Perkins, S. M. Subsequent malignancies and their effect on survival in patients with retinoblastoma. Pediatr. Blood Cancer 61, 116–119 (2014).
Ford, J. S., Chou, J. F. & Sklar, C. A. Attendance at a survivorship clinic: impact on knowledge and psychosocial adjustment. J. Cancer Surviv. 7, 535–543 (2013).
Schulz, C. J., Riddle, M. P., Valdimirsdottir, H. B., Abramson, D. H. & Sklar, C. A. Impact on survivors of retinoblastoma when informed of study results on risk of second cancers. Med. Pediatr. Oncol. 41, 36–43 (2003).
Rowland, E. & Metcalfe, A. Communicating inherited genetic risk between parent and child: a meta-thematic synthesis. Int. J. Nurs. Stud. 50, 870–880 (2013).
Clarke, S. A., Sheppard, L. & Eiser, C. Mothers’ explanations of communicating past health and future risks to survivors of childhood cancer. Clin. Child Psychol. Psychiatry 13, 157–170 (2008).
Weaver, R. R. Seeking high reliability in primary care: leadership, tools, and organization. Health Care Manage. Rev. 40, 183–192 (2014).
Jha, P. et al. Prospective study of one million deaths in India: rationale, design, and validation results. PLoS Med. 3, e18 (2006).
Farmer, P. Who lives and who dies? Lond. Rev. Books 30, 17–20 (2015).
Ladas, E. J. et al. Improving our understanding of the use of traditional complementary/alternative medicine in children with cancer. Cancer 121, 1492–1498 (2015).
Farmer, P. & Mukherjee, J. Ebola: countries need ‘staff, stuff, and systems’. PIH [online], (2014).
Panton, R. L. et al. A visual approach to providing prognostic information to parents of children with retinoblastoma. Psychooncology 18, 300–304 (2009).
Grossmann, C., Sanders, J. & English, R. A. Large Simple Trials and Knowledge Generation in a Learning Health System: Workshop Summary (National Academies Press, 2013).
Laurie, N. A. et al. Inactivation of the p53 pathway in retinoblastoma. Nature 444, 61–66 (2006).
Pritchard, E. M. et al. Pharmacokinetics and efficacy of the spleen tyrosine kinase inhibitor r406 after ocular delivery for retinoblastoma. Pharm. Res. 31, 3060–3072 (2014).
Mahida, J. P. et al. A synergetic screening approach with companion effector for combination therapy: application to retinoblastoma. PLoS ONE 8, e59156 (2013).
Taich, P. et al. Clinical pharmacokinetics of intra-arterial melphalan and topotecan combination in patients with retinoblastoma. Ophthalmology 121, 889–897 (2014).
Carcaboso, A. M. et al. Episcleral implants for topotecan delivery to the posterior segment of the eye. Invest. Ophthalmol. Vis. Sci. 51, 2126–2134 (2010).
Kang, S. J., Durairaj, C., Kompella, U. B., O’Brien, J. M. & Grossniklaus, H. E. Subconjunctival nanoparticle carboplatin in the treatment of murine retinoblastoma. Arch. Ophthalmol. 127, 1043–1047 (2009).
Oronsky, B. et al. The war on cancer: a military perspective. Front. Oncol. 4, 387 (2014).
The World Bank Group. Data. World Bank[online], (2015).
Wang, H. et al. Skp2 is required for survival of aberrantly proliferating Rb1-deficient cells and for tumorigenesis in Rb1+/− mice. Nat. Genet. 42, 83–88 (2010).
Chan, C. H. et al. Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell 154, 556–568 (2013).
T.W.C. acknowledges US NIH National Center for Advancing Translational Sciences grant KL2TR001106 and support from Research to Prevent Blindness, Inc. D.C. acknowledges NIH grant R01CA137124 and support from the Larry and Celia Moh Foundation and the Margaret E. Early Medical Research Trust. H.D. and B.L.G. acknowledge the TUYF Charitable Trust (Hong Kong).
The authors declare no competing interests.
About this article
Cite this article
Dimaras, H., Corson, T., Cobrinik, D. et al. Retinoblastoma. Nat Rev Dis Primers 1, 15021 (2015). https://doi.org/10.1038/nrdp.2015.21
This article is cited by
Journal of Experimental & Clinical Cancer Research (2022)
LncRNA HOTAIR facilitates proliferation and represses apoptosis of retinoblastoma cells through the miR-20b-5p/RRM2/PI3K/AKT axis
Orphanet Journal of Rare Diseases (2022)
Nature Reviews Molecular Cell Biology (2022)
Interruption of aberrant chromatin looping is required for regenerating RB1 function and suppressing tumorigenesis
Communications Biology (2022)
Cell Death & Disease (2022)